EU label for nilotinib now includes info on stopping therapy

Print Friendly, PDF & Email


CML cells
Image by Difu Wu
The European Commission has approved the inclusion of treatment-free remission (TFR) data in the European Union (EU) product information for nilotinib (Tasigna®). TFR is the ability to maintain molecular response after stopping tyrosine kinase inhibitor (TKI) therapy in patients with Ph+ chronic myeloid leukemia in chronic phase (CML-CP). Nilotinib... [Read Article]
Print Friendly, PDF & Email

Dasatinib potentially a new SOC for children with CML-CP, study author suggests

Print Friendly, PDF & Email


Child with cancer
Photo by Bill Branson
The largest ongoing and prospective trial of pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP), according to the best knowledge of the investigators, has found dasatinib to be safe and effective as first- or second-line therapy for these children. Patients refractory to or intolerant of imatinib... [Read Article]
Print Friendly, PDF & Email